当前位置:

网站首页>文章详情

不同剂量替罗非班对急性冠脉综合征患者<br />PCI术后疗效及安全性观察

【PDF在线阅读】 【下载PDF】

摘要:

目的 研究不同剂量替罗非班对急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)术后
疗效及安全性。方法 选择2016年1月至2019年12月于解放军总医院第一医学中心诊断为急性冠脉综合征
(ACS)且接受直接PCI治疗的661例患者作为研究对象进行作回顾性分析。根据治疗方法不同,将患者分
为替罗非班常规剂量组(346例)及替罗非班低剂量组(315例),对比两组患者的基线数据、出血事件、
缺血事件及主要不良心血管事件(MACE)发生率情况。结果 两组患者的基线数据无统计学差异,与常
规剂量组相比,替罗非班低剂量组不增加患者出血事件(P=0.274),缺血事件(P=0.324)及MACE事件
(P=0.208)发生风险。结论 ACS患者PCI围手术期应用低剂量替罗非班具有较好的安全性与可靠性。

Abstract:

Objective To study the curative effect and safety of tirofiban in different doses in patients with acute
coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods ACS patients undergone PCI (n=661)
were chosen from the First Medical Center of Chinese PLA General Hospital from Jan. 2016 to Dec. 2019 and given
retrospective analysis. All patients were divided, according to different therapies, into routine-dose tirofiban group
(n=346) and low-dose tirofiban group (n=315). The baseline data and incidence rates of bleeding events, ischemic events
and major adverse cardiovascular events (MACE) were compared between 2 groups. Results The baseline data had no
statistical difference between 2 groups. The risks of bleeding events (P=0.274), ischemic events (P=0.324) and MACE
(P=0.208) did not increase in low-dose tirofiban group compared with those in routine-dose tirofiban group. Conclusion
During peri-PCI period low-dose tirofiban has higher safety and reliability in ACS patients.

基金项目:

参考文献:

  • 2008

  • 1

通讯地址:北京市东城区东四十条南门仓5号
电话: 237499284 邮编:100700
网址:www.ebcvm..org Email: ebcvm_cj@126.com

copyright © 《中国循证心血管医学杂志》编辑部
当您在使用本网站投稿遇到困难时,
请拨打400-921-9838
或直接将稿件投送到编辑部邮箱ebcvm_cj@126.com